The state and federal regulatory status of medical marijuana, tetrahydrocannabinol (THC), and cannabidiol (CBD) is conflicting and ever-changing. This course guides pharmacists on how to interpret these conflicting regulations as they shift, as well as provides the FDA’s perspective on the legality of CBD as an unapproved drug.

Upon successful completion of this knowledge-based CPE course, pharmacists should be able to:
1. Discuss the conflict of laws between states that have legalized marijuana for medical or recreational use, and the federal government approach that continues to classify marijuana as an illegal drug.
2. Review implications of the 2018 Farm Bill that legalized the distribution of CBD under some circumstances.
3. Explain the FDA perspective on the legality of cannabidiol (CBD) as an unapproved new drug.

David B. Brushwood, R.Ph, J.D.
Senior Lecturer, The University of Wyoming School of Pharmacy
Pharmacy Law Content Developer, CEimpact

David B. Brushwood has no relevant financial relationships with ineligible companies to disclose.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: January 28, 2024
Planned Expiration Date: January 28, 2027

This course is provided for educational purposes. CEimpact is not a law firm and does not provide legal advice of any kind. For legal advice, please contact a licensed attorney.

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.

RN-10.23